COCP News Alert Cocrystal Pharma Inc. (COCP) 0.4450 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cocrystal Pharma Inc. (COCP) 0.4450 $COCP

Cocrystal Pharma: Small Cap Company With Transformative Merger
Leonard Yaffe - at Seeking Alpha - Thu Nov 27, 12:51PM CST


Cocrystal and RFS complete marriage
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 11:59AM CST


Cocrystal Pharma and RFS Pharma Merge to Create Advanced Antiviral Development Organization
Marketwired - Tue Nov 25, 8:52AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, LLC, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi. Since 2004, RFS Pharma has been working on the development of innovative drugs to treat human viral diseases.
OPK: 9.63 (+0.21)

Cocrystal Pharma Reports Third Quarter Financial Results and Select Program Updates
Marketwired - Fri Nov 14, 8:15AM CST
Cocrystal Pharma, Inc. (the "Company" (OTCQB: COCP), a biotechnology company focused on developing new antiviral therapeutics for human diseases, today reported financial results for the third quarter ended September 30, 2014.

Cocrystal Pharma Develops Novel Ebola Screening Technology
Marketwired - Thu Oct 23, 8:26AM CDT
Cocrystal Pharma, Inc. (OTCBB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.
OPK: 9.63 (+0.21)

Cocrystal Pharma records higher Q2 operating expenses of USD1.4m
M2 - Mon Aug 18, 7:46AM CDT
Biotechnology company Cocrystal Pharma (OTC BB:COCP) stated on Friday that its operating expenses were USD1.4m for the second quarter ended 30 June 2014.

Cocrystal Pharma Reports Second Quarter Financial Results
Marketwire - Fri Aug 15, 6:30AM CDT
Cocrystal Pharma, Inc. (the "Company" (OTCBB: COCP) (OTCQB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported financial results for the second quarter ended June 30, 2014.

Cocrystal Pharma, Inc. - "World Hepatitis Day and a Continued Global Unmet Medical Need"
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
New York, NY / July 28, 2014 / Cocrystal Pharma, Inc. (OTCBB: COCP) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Gary Wilcox. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

OTC Stocks Trading News: Cocrystal Pharma, Inc. Minerco Resources, Inc. MediJane Holdings, Inc. Applied DNA Sciences, Inc. mCig Inc
PR Newswire Europe - Tue Jul 22, 7:02AM CDT
LONDON, July 22, 2014 /PRNewswire/ --
APDN: 3.01 (+0.01)

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CVM: 0.62 (+0.03), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), NNVC: 2.68 (-0.14), SIGA: 1.43 (-0.03), JNJ: 104.59 (+0.31), OPK: 9.63 (+0.21), XOMA: 3.68 (+0.11), NVS: 93.91 (+0.66)

Rhinovirus Infection - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rd8bmd/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Alios BioPharma, Inc. - Cocrystal Pharma, Inc. - Sealife PHARMA GMBH - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rd8bmd/rhinovirus
BOTA: 2.26 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 69

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading

Top 5 Most Recently Viewed Articles

An In-Depth Analysis of Qorvo's Current Short Interest Trends

Updated Category News Views 215

Understanding Qorvo's Short Interest Movement Qorvo Inc. (NASDAQ: QRVO) has been experiencing notable changes in its short interest, with a recent report indicating a decrease of 16.17%. This drop reflects a total of 5.20 million shares sold short, equating to about 7.67% of the total shares available for trading. Traders should note that, with the current trading volume,...

Continue Reading
Sev1Tech Secures $188M Contract with U.S. Space Force

Updated Category News Views 167

Sev1Tech Secures a Major Contract with the U.S. Space Force Sev1Tech has recently made headlines by being awarded a substantial contract valued at $188 million from the U.S. Space Force (USSF), specifically under the Space Systems Command (SSC). This contract involves expanding the support for an innovative and powerful network known as meshONE-T. This network is...

Continue Reading
Exploring Rigetti Computing's Growth and ETF Impact

Updated Category News Views 339

Understanding the Surge of Rigetti Computing Rigetti Computing Inc. (NASDAQ: RGTI) has seen an extraordinary performance recently, with its shares rising a staggering 100% year-to-date, and almost 3,900% over the past year. This impressive increase has attracted considerable investor interest, particularly from those focused on opportunities in the rapidly evolving...

Continue Reading
Kratos Defense Stock Climbs High: What Investors Should Know

Updated Category News Views 198

Kratos Defense Stock Reaches New Heights Kratos Defense (NASDAQ: KTOS) has recently achieved a remarkable milestone by hitting a 52-week high of $30.42. This achievement comes amid a strong defense market, marking a significant increase in the company's stock value with a one-year growth of 55.96%. Investors demonstrate growing confidence in Kratos, renowned for its...

Continue Reading
Precision Linear Actuators for Optical and Automation Needs

Updated Category News Views 143

High-Precision Micro-Positioning Solutions Available For those seeking reliability and accuracy in optical alignment, precision automation, and research applications, the latest offerings from PI deliver exceptional results. Introducing the L-220 Series Linear Actuators PI’s L-220 series linear actuators are designed for applications demanding sub-micrometer precision....

Continue Reading